key: cord-0746572-okg9ruxu
authors: Padilla, Luz A.; Collins, Jacqueline L.; Idigo, Adeniyi J.; Lau, Yung; Portman, Michael A.; Shrestha, Sadeep
title: Kawasaki Disease and Clinical Outcome Disparities among Black Children
date: 2020-09-24
journal: J Pediatr
DOI: 10.1016/j.jpeds.2020.09.052
sha: dac71ce61d3af8709a59a55063ef1b3f4ee98ee1
doc_id: 746572
cord_uid: okg9ruxu

STUDY DESIGN: ICD codes were used to identify children with Kawasaki disease admitted to a tertiary Southeast U.S. center. Subjects diagnosed and treated according to AHA criteria were included. Demographic, laboratory, clinical and echocardiographic data from EMR (2000-2015) were compared between Blacks and Whites. RESULTS: Data from 369 subjects (52% Whites and 48% Blacks) were included in our analysis. No significant differences related to timely admission, IVIG treatment or, coronary artery abnormalities during hospitalization were observed, Blacks showed lower IVIG response rates for those administered IVIG within 10 days of fever onset (86.6% vs 95.6%, P = 0.007). Blacks received more ancillary drugs (9.6% vs 2.6%, P value 0.003), and endured longer hospitalizations (5±3.9 vs 3.4±2.2 days, P = 0.001). Blacks presented with higher C-reactive protein, erythrocyte sedimentation rate and; lower hemoglobin, albumin and, sodium. Blacks showed a greater proportion of persistent coronary artery abnormalities at follow-up when compared with Whites (14.5% vs 6.3%, P = .03, second follow-up ECHO; 21.2% vs 6.9%, P = 0.01 third follow-up ECHO). CONCLUSION: Black children with Kawasaki disease had higher IVIG refractory prevalence, severe inflammation, received more ancillary treatments and, longer hospitalizations than White children. Despite no racial differences in time to diagnosis or initial treatment, there was higher coronary artery abnormality persistence among Black children at follow-up.

Hispanic Whites, but remains lower than children of Asian descent. (2) Furthermore, studies have suggested that racial and ethnic discrepancies also exist for treatment response. (3) (4) (5) Dionne et al showed that lower socioeconomic status is associated with delayed treatment, prolonged length of stay, and increased risk of large/giant coronary artery aneurysm. (6) However, the lowest SES quartile cohort had much greater proportion of Black children than the three higher quartiles combined. Thus, the potential influence of race as a factor influencing these outcome measures could not be eliminated. A small retrospective study reported a lower risk of CAA in Black children. (7) In contrast, two studies OF Black children indicated that they were at greater risk of non-response to IVIG or had poorer CA outcomes. (5, 8) The hypothesis that Black race poses a risk factor for poorer KD outcomes requires further exploration. We performed a retrospective analysis to determine if there were any differences in KD characteristics and clinical outcomes among Black children compared with White children, and if any disparities were due to differences in healthcare delivery or biological factors.

After ethical approval was obtained, we identified patients with Kawasaki disease admitted to the Children's of Alabama hospital from January 2000 through May of 2015. A hospital administrative database (PedCards) was queried using ICD-9 (446.1) and ICD-10 (M30.3) codes for mucocutaneous lymph node syndrome (Kawasaki disease). The initial query yielded 587 records. We screened these records to remove duplicates and then excluded patients who did not meet inclusion and exclusion criteria from our analyses. Only those children with assigned race by parent report in their record as White or Black were included. Subjects were specifically excluded if they did not meet American Heart Association (AHA) (2004, 2017) KD J o u r n a l P r e -p r o o f 5 diagnostic criteria (9, 10); they were transferred from an outside institution more than 36 hours after completing IVIG treatment infusion or; if documentation received at patient transfer was inadequate. Non-IVIG response or IVIG refractoriness was defined as persistent or recurrent fever extending 36 hours after completion of IVIG treatment. (11) Baseline demographics, hospital and laboratory clinical data, 2-D echocardiography (ECHO) during the hospitalization and, outpatient follow-up data were extracted from their electronic medical records manually and entered into Research Electronic Data Capture (REDCap). (12) The z-scores for the left anterior descending, right coronary artery and left main coronary artery were calculated using regression models as described by McCrindle et al using the following website: http://www.parameterz.com/sites/coronary-arteries.(13) An abnormal echocardiogram (ECHO) was defined as having a z-score ≥ 2.5 or reported aneurysm for any of the three CA.(9, 14) Hospital ECHO readings were classified as "yes" for changes if any increase in diameter (>20%) occurred for any of the CA.(3) When available, the subsequent three follow-up outpatient ECHO examinations after discharge were extracted.

Descriptive statistics (frequencies, percentages, medians, interquartile ranges [Q1-Q3], means and, standard deviations) of demographics, clinical and laboratory variables were used to summarize the data between the two racial groups. Differences between the two groups were compared using the chi-square and the Fisher exact test for categorical variables, student t-test, and Wilcoxon rank sum test for continuous variables where appropriate. If data for a subject were missing for a particular variable it would be excluded from that variable analysis. Statistical Analytical Software (SAS) 9.4 (SAS institute, Cary, NC) was used for the analysis and all statistical tests of a two-sided P value of < 0.05 were considered significant. Comparisons of J o u r n a l P r e -p r o o f 6 racial clinical and laboratory characteristics were further stratified by IVIG responders and nonresponders using similar descriptive statistical methods.

We analyzed a final cohort of 369 patients (192 Whites and 177 Blacks) after applying the inclusion and exclusion criteria ( Figure 1 ). Between the two races, there were no significant differences in age at admission or sex (Table 1) . White children presented more frequently with conjunctivitis (66.7% vs 55.4%; P value 0.03) and rash (72.4% vs 58.2%; P value 0.004) than Black children. There were no other significant differences in clinical presentation. Table 2 shows the clinical laboratory data by race and eventual response to IVIG.

Hematologic variables at admission were significantly different between black and white children. Mean hemoglobin (10.6±1.2 vs 11.2±1.2; P value <0.0001) and hematocrit levels were also lower in Blacks (P values <0.001). Few significant laboratory differences occurred between either Black or White children when comparing IVIG response. Discharge laboratory data were lacking for the majority of patients and is shown in Table 3 (available at www.jpeds.com). In general, laboratory variables for both groups trended to be more normal at discharge. For this select patient group with data, we noted that discharge CRP though lower J o u r n a l P r e -p r o o f 7 than admission for both races remained higher for Black children and, that Black children had lower Alanine Aminotransferase levels than White children (P value 0.04).

Differences in presentation were not due to disparity in time to treatment (initiation of IVIG infusion) or healthcare delivery. Time from fever onset to admission was shorter for Blacks (P value 0.05); and no difference occurred for time from admission to IVIG treatment (P value 0.12). For all patients receiving IVIG, regardless of the number of days from fever onset to infusion, there were no differences in response between the racial groups. Ninety-four percent of Black children and 89.7% of the White children received IVIG within 10 days of fever onset, per the AHA guidelines (Table I) . Among those treated with IVIG within the first 10 days after fever onset, Black children had a lower IVIG response rate when compared with Whites (86.6% vs 95.6%; P value 0.007). More Black children than White children received alternative therapies (9.6% vs 2.6%; P value 0.003) and a smaller proportion of them were left untreated (2.8% vs 7.3%; P value 0.04). Black children also averaged longer lengths of hospital stay ( Figure 2 ; available at www.jpeds.com) (4.5±3.9 vs 3.4±2.2; P value 0.002). Table 1 illustrates echocardiographic data for the KD hospitalization. The first ECHO was performed at an equivalent time for the two groups. The small portion of patients without an initial inpatient ECHO had their ECHO performed as an outpatient prior to their admission. The percentage of abnormal ECHOs was similar in the two groups though there was a trend towards performing more subsequent ECHOs during the hospitalization among Black children. Table 4 shows outpatient ECHO data. Overall, the two groups showed similar numbers of repeat ECHOs and follow-up time frames. However, a significantly greater proportion of persistent CA dilation or aneurysm (Z > 2.5) was observed in Black children compared with White children at follow-J o u r n a l P r e -p r o o f 8 up (second follow-up ECHO abnormality 14.5% vs 6.3%, P value 0.03 and third follow-up ECHO abnormality 21.2% vs 6.9%, P value 0.01; Table 4 ). For those who had abnormal followup ECHOs, there were no differences between the median z-scores for any of the three CA between the two races.

The subjects in this study were from areas throughout Alabama, a state considered representative of populations in the deep South U.S; where 65.3% of the population is White (not Hispanic or Latino), and 26.8% are Black. (15) We found that Black children with Kawasaki disease show greater prevalence of IVIG refractoriness and greater persistence of CA abnormalities at follow-up. Two studies with much smaller populations paralleled the findings of our study. (4, 5) In those studies, Black children also exhibited higher prevalence of IVIG resistance or greater persistence of CA abnormalities. Contradicting these findings, a single study of an urban center with a predominantly Black population suggested that African American descent was protective from developing CAA.(7) However, that study did not provide clearly defined criteria for CAA, and lacked a comparable size White population. Furthermore, time to treatment specifically by race has not been examined in previous studies. Thus, questions remained on whether disease outcome disparity occurs as a result of socioeconomic status, timely access, healthcare delivery, or to a true biologic/genetic variation. In this study, from a region, traditionally known for racial disparities including access,(16) we found no difference in time to admission after fever, follow-up or healthcare delivery. Additionally, racial differences in clinical presentation did not appear to impact time to diagnosis or treatment. Because KD diagnosis depends on patients meeting published clinical and laboratory criteria, treatment with J o u r n a l P r e -p r o o f 9 IVIG is not initiated until after 4 or 5 days of persistent fever. Overall, our data showed no deviation from this practice, in either race.

In contrast, though demographics, timing for admission and, treatment were near equivalent for the two racial groups, we observed differences in laboratory values at admission.

CRP was near double in Black children and ESR was also higher compared with White children.

Tennessee.(4) Our data suggest that the innate or inflammatory response to an unknown environmental trigger in Black children with KD may be more extreme. Prior studies have compared innate response in general European (Dutch) and African (Gabonese) children, but the differences in inflammatory responses were observed in relation to different pathogen stimuli at two geographical regions and not with race. (17) In this study, we examined children living in the same state, suggesting that differences in immune response could potentially be due to genetics, although cultural or environmental exposure discrepancies cannot be ruled out. Studies in adults show that African ancestry specifically predicts a stronger inflammatory response to pathogens, and this response may have an evolutionary and genetic basis that could have broad implication 

Limitations for our study relate principally to its retrospective nature, which includes missing data or, was limited by what was reported in notes from healthcare professionals in the electronic medical records. Laboratory data are not routinely collected for patients with Kawasaki disease in most centers following treatment except for special circumstances or among those with poor clinical evolution. Therefore, a paucity of second laboratory values exist for our cohort. Likewise, some longitudinal data were missing as patients were frequently not followed, specifically after normal CA results. We noted a trend towards obtaining more repeat inpatient echocardiograms in Black children. This trend could be due to longer hospital stays and the higher rate of non-responders prompting requests for additional studies (Figure 2 ). The vast majority of patients were seen again after an abnormal ECHO, thereby minimizing important data loss and protecting integrity of our CA persistence results. For this same reason a decrease in the number of overall echocardiograms performed over time could affect the positivity rate.

Furthermore, this drop in the denominator for ECHOs may be due to patients continuing their follow-up elsewhere. Categorical risk level of CAs was not feasible due to the small numbers of those with abnormal z-scores. Our results are from a single center and may lack generalizability to other populations. Lastly, there may also be selection bias as these were patients referred to or hospitalized at a tertiary care hospital.

For the most part, race has rarely been accounted for in predictive models or during statistical analyses for clinical trials. Therefore, evaluation of these risks scores by race, specifically in Blacks is warranted. 

The Epidemiology and Pathogenesis of Kawasaki Disease

Hospitalizations for Kawasaki syndrome among children in the United States

Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial

Predictors of Intravenous Immunoglobulin Nonresponse and Racial Disparities in Kawasaki Disease

Kawasaki Disease Outcomes and Response to Therapy in a Multiethnic Community: A 10-Year Experience

Socioeconomic Status on Outcomes of Patients with Kawasaki Disease

The epidemiology of Kawasaki disease 16

Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young

Children After Primary Treatment for Kawasaki Disease

Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support

Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements

Coronary Artery Aneurysms in Kawasaki Disease: Risk Factors for Progressive Disease and Adverse Cardiac Events in the US Population

Quick Facts: Alabama

The health status of southern children: a neglected regional disparity

Differences in innate cytokine responses between European and African children

Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2: A Systematic Review

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents

Associated Multisystem Inflammatory Syndrome in Children -United States

Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort

Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial

Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease

Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebocontrolled trial

Predictive risk factors of coronary artery aneurysms in Kawasaki disease

Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance

Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population